Tyra Biosciences prices $400M offering of common stock and pre-funded warrants

Tyra Biosciences, Inc.

9,079,000 shares priced at $22.03; pre-funded warrants for 9,078,529 shares at $22.029.
Gross proceeds expected ~$400.0M; closing expected September 15, 2026.
Net proceeds to advance dabogratinib in LG-UTUC, IR NMIBC, and achondroplasia programs.
Offering led by RA Capital; Jefferies, Guggenheim, Cantor, Barclays, William Blair as book-runners.
Warrants exercisable at $0.001; beneficial ownership limits selectable up to 19.99%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.